IntelGenx announces multiple commercialization agreements with Chemo Group in 2017

By Melissa Fassbender

- Last updated on GMT

Related tags Corporation

Founded in 1978, Chemo Group markets more than 300 products.(Image: Chemo Group)
Founded in 1978, Chemo Group markets more than 300 products.(Image: Chemo Group)
IntelGenx Corp has granted Chemo Group an exclusive worldwide license to commercialize several products – moving the company into the novel drug delivery market.

Chemo has signed four products with us in 2017​,” Edward Miller, Director, IR and Corporate Communications at IntelGenx, told Outsourcing-Pharma.com. “We will work with Chemo to develop these products to commercialization​.”

According to the oral drug delivery company company, the combined total market of the four products is more than $7bn. The partnership could also present future opportunities for further product agreements.

Per the agreement, IntelGenx is entitled to an upfront payment, development costs of the product and future milestone payments. A total value of which is in the seven digits, according to IntelGenx.

The companies will share the commercialization profits.

IntelGenx also recently built a new oral film development and manufacturing facility in Montreal, Canada. Construction was completed in Q1 2016 and the facility is expected to be fully operational by Q1 2017. The 17,000 sq ft facility features high capacity manufacturing and packaging equipment.

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Related suppliers

Follow us

Webinars

Headlines